Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

0.4893 +0.0005 (+0.10%)
Streaming Delayed Price Updated: 10:12 AM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bluebird Bio

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Peeling Back The Layers: Exploring bluebird bio Through Analyst Insights
Via Benzinga
BLUE LOSS ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
From The Rosen Law Firm, P.A.
Via Business Wire
Kaplan Fox & Kilsheimer LLP Investigates bluebird bio, Inc. (NASDAQ: BLUE)
NEW YORK, NY - (NewMediaWire) - March 26, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click... 
Via NewMediaWire
Kaplan Fox &amp; Kilsheimer LLP Investigates bluebird bio, Inc. (NASDAQ: BLUE)
NEW YORK, NY - (NewMediaWire) - March 26, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click... 
Via TheNewswire.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Peering Into bluebird bio's Recent Short Interest
Via Benzinga
Is Bluebird Bio Stock a Buy Now?
Are you feeling brave? 
Via The Motley Fool
Forecasting The Future: 6 Analyst Projections For bluebird bio
Via Benzinga
bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
From bluebird bio, Inc.
Via Business Wire
Earnings Scheduled For March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. 
Via Benzinga
bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call
From bluebird bio, Inc.
Via Business Wire
(BLUE) - Analyzing bluebird bio's Short Interest
Via Benzinga
Why Bluebird Bio Stock Flew Higher Than the Market Today
The company was thrown a financial lifeline. 
Via The Motley Fool
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
From bluebird bio, Inc.
Via Business Wire
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place 
Via MarketBeat
Why Bluebird Bio Stock Dived Into the Red on Tuesday
The biotech has had a tough time of it over the past few years; a pundit's revised take on the company won't improve that situation. 
Via The Motley Fool
MarketBeat Week in Review – 2/26 - 3/1
As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to invest 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
bluebird bio Stock Signals Potential to be a Multi-bagger
Driving a bargain of a short squeeze play, Bluebird Bio stock could soon announce what every investor is hoping to hear, here's what management could do 
Via MarketBeat
Topics Economy
Exposures Economy
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
Both companies are working on treatments for genetic disorders. 
Via Investor's Business Daily
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. 
Via Benzinga
bluebird bio: How to play LEAPS options for growth and income
Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT 
Via MarketBeat
Exposures Product Safety
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
bluebird bio stock is ripe for a 400% institutional short squeeze
Bluebird Bio stock could be on the verge of a 400% pop on earnings, management has set the writing on the wall for institutional buying to trickle in 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Is CRISPR Therapeutics the NVIDIA of gene editing?
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Gene therapy: Why does it cost millions for a single treatment?
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. 
Via MarketBeat
Exposures Product Safety
If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today
The answer hardly inspires confidence. 
Via The Motley Fool
Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the... 
Via Benzinga
Exposures Product Safety
2 Red Flags for Bluebird Bio Stock
The biotech's struggles may continue. 
Via The Motley Fool
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe 
Via MarketBeat
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.